COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART study.Arm 2: Effect of daily Interferon-alpha on cancer patients with known positive contact with COVID-19.

Peter MacCallum Cancer Centre0 个研究点目标入组 170 人开始时间: 2020年8月26日最近更新: 2023年12月12日

适应症

试验速览

暂无简介。

•1. Age equal to or greater than 18 years old.
•2. Any haematological or solid tumour
•3. Current or within the last 12 months received cancer related treatment such as chemotherapy, radiotherapy or targeted small molecule, cellular therapy or immune-modulating therapy
•4. Signed written and verbal informed consent
•5. Have been exposed to a known COVID-19 case within the last 72 hours, defined by the current Department of Health and Human services such as household contact, 15 minutes of face to face exposure, 2 hours in close space.
•6. Willingness to inform the study nurse/co-ordinator of COVID-19 testing
•7. Willingness to perform a self-collect nose/throat swab

•1. Previous diagnosis of COVID-19 (microbiologically proven, either symptomatic or asymptomatic)
•2. Any contra-indication to intra-nasal IFN-a such as severe nasal bleeding requiring intervention, nasal malignancy, nasal deformity, radiotherapy to the nasopharynx and/or oropharynx
•3. Pregnant or breast-feeding women, or women who wish to become pregnant during the course of the study
•4. Patient unable to return for follow-up
•5. Life expectancy of less than 1 month
•6. Patient already included in another intervention study on the prevention of COVID-19
•7. Currently unwell with influenza-like symptoms

发起方

Peter MacCallum Cancer Centre